Copay help by condition · Hormone, bone and metabolic · read 2026-11-08
Obesity: which charitable copay funds are open
The one fund we hold for Obesity is closed or at capacity right now (read 2026-11-08).
Funds fill and reopen. Use the alert below, ask the manufacturer's program for your drug (see the assistance finder), and check your state's Medicaid coverage.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Obesity
- Closed or at capacityObesity
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $2,000Insurance supported: Any health insurance
The page lists the fund as Closed. Source page
Drugs whose FDA label names Obesity
3 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 2 have a program (in our assistance finder or on the program's own page) and 1 has a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Ozempic Semaglutide Every route for this drug | ... o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition. Label on openFDA, read 2026-11-10 | Ozempic Savings (via NovoCare) Limited Wegovy Savings (via NovoCare) Novo Nordisk PAP (NovoCare) Limited 0.5 mg, 1 mg, or 2 mg and 1 more | $274.00 for a 30-day supply, effective 2027-01-01 |
| Mounjaro Tirzepatide Every route for this drug | ... to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. Label on openFDA, read 2026-11-10 | Mounjaro Savings (via Lilly) Diabetes Medication Assistance (Multiple Programs) | not in the CMS negotiated-price file |
| Victoza 3-Pak Liraglutide | Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
Related conditions
No broader or more specific condition page for this one.
Group: Hormone, bone and metabolic. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: obesity.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Obesity?
As read on 2026-11-08, none of the 1 funds we hold for Obesity say they are open. Funds reopen, so use the alert on this page.
Which organizations run funds for Obesity?
TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.